Beigene Ltd
ONC249.835USD
+4.935+2.02%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
24.45BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Beigene Ltd Unternehmen
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Unternehmensinformationen
Unternehmens-codeONC
Name des UnternehmensBeigene Ltd
IPO-datumFeb 03, 2016
Gegründet am2010
CEOMr. John Victor Oyler
Anzahl der mitarbeiter11000
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 03
Addressec/o Mourant Governance Services (Cayman)
StadtGRAND CAYMAN
BörseThe Toronto Stock Exchange
LandCayman Islands
PostleitzahlKY1-1108
Telefon13459494123
Websitehttps://www.beigene.com/
Unternehmens-codeONC
IPO-datumFeb 03, 2016
Gegründet am2010
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Xiaobin Wu ,
Xiaobin Wu ,
President, Chief Operating Officer, General Manager - China
President, Chief Operating Officer, General Manager - China
16.36K
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Director
Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Qingqing (Michael) Yi
Mr. Qingqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Xiaobin Wu ,
Xiaobin Wu ,
President, Chief Operating Officer, General Manager - China
President, Chief Operating Officer, General Manager - China
16.36K
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Director
Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Qingqing (Michael) Yi
Mr. Qingqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Umsatzaufteilung
Währung: USDUpdate-Zeit: Sun, Apr 6
Währung: USDUpdate-Zeit: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product
3.72B
97.62%
BRUKINSA
2.64B
69.40%
Tislelizumab
620.84M
16.29%
XGEVA
224.40M
5.89%
BLINCYTO
74.33M
1.95%
Other
-3.47B
-91.15%
Nach RegionUSD
Name
Umsatz
Anteil
United States
1.96B
51.37%
China
1.41B
37.04%
Europe
362.63M
9.52%
ROW
78.81M
2.07%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product
3.72B
97.62%
BRUKINSA
2.64B
69.40%
Tislelizumab
620.84M
16.29%
XGEVA
224.40M
5.89%
BLINCYTO
74.33M
1.95%
Other
-3.47B
-91.15%
Aktionäre
Update-Zeit: Sat, Apr 26
Update-Zeit: Sat, Apr 26
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Amgen Inc
19.15%
Baker Bros. Advisors LP
8.90%
Capital International Investors
6.18%
PRIMECAP Management Company
5.16%
Baillie Gifford & Co.
3.71%
Other
56.90%
Aktionärsstatistik
Aktionäre
Anteil
Amgen Inc
19.15%
Baker Bros. Advisors LP
8.90%
Capital International Investors
6.18%
PRIMECAP Management Company
5.16%
Baillie Gifford & Co.
3.71%
Other
56.90%
Art
Aktionäre
Anteil
Investment Advisor
24.19%
Corporation
19.18%
Hedge Fund
10.24%
Investment Advisor/Hedge Fund
5.05%
Sovereign Wealth Fund
2.00%
Research Firm
0.94%
Pension Fund
0.17%
Bank and Trust
0.10%
Family Office
0.02%
Other
38.11%
Institutionelle Beteiligung
Update-Zeit: Mon, Jan 20
Update-Zeit: Mon, Jan 20
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
541
67.04M
67.87%
+1.41M
2024Q4
575
70.01M
71.38%
+1.65M
2024Q3
603
67.03M
68.90%
-2.04M
2024Q2
601
66.99M
69.35%
-2.19M
2024Q1
621
66.56M
67.86%
-955.35K
2023Q4
626
65.12M
66.49%
-3.71M
2023Q3
632
67.27M
67.88%
-2.05M
2023Q2
655
66.79M
67.58%
-3.13M
2023Q1
655
67.68M
71.16%
-4.10M
2022Q4
657
69.40M
73.25%
-5.85M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Amgen Inc
18.94M
19.16%
--
--
Feb 20, 2025
Baker Bros. Advisors LP
8.80M
8.9%
-732.83K
-7.69%
Feb 28, 2025
Capital International Investors
6.11M
6.18%
-317.72K
-4.94%
Dec 31, 2024
PRIMECAP Management Company
5.10M
5.16%
+124.61K
+2.51%
Dec 31, 2024
Baillie Gifford & Co.
3.67M
3.71%
-34.56K
-0.93%
Dec 31, 2024
Fidelity Management & Research Company LLC
1.78M
1.8%
+174.46K
+10.84%
Dec 31, 2024
Temasek Holdings Pte. Ltd.
1.53M
1.54%
-863.25K
-36.14%
Dec 31, 2024
T. Rowe Price Associates, Inc.
1.49M
1.51%
+109.68K
+7.93%
Dec 31, 2024
T. Rowe Price International Ltd
1.44M
1.46%
+127.40K
+9.67%
Dec 31, 2024
HHLR Advisors, Ltd.
1.32M
1.34%
-2.48M
-65.19%
Mar 03, 2025
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
First Trust NYSE Arca Biotechnology Index Fund
4.79%
Tema Oncology ETF
4.29%
Virtus LifeSci Biotech Products ETF
2.43%
Global X Aging Population ETF
2.13%
VanEck Biotech ETF
2.09%
iShares Health Innovation Active ETF
1.49%
iShares Biotechnology ETF
1.39%
Invesco Nasdaq Biotechnology ETF
1.15%
ProShares Ultra Nasdaq Biotechnology
1.14%
National Security Emerging Markets Index ETF
0.92%
Mehr Anzeigen
First Trust NYSE Arca Biotechnology Index Fund
Anteil4.79%
Tema Oncology ETF
Anteil4.29%
Virtus LifeSci Biotech Products ETF
Anteil2.43%
Global X Aging Population ETF
Anteil2.13%
VanEck Biotech ETF
Anteil2.09%
iShares Health Innovation Active ETF
Anteil1.49%
iShares Biotechnology ETF
Anteil1.39%
Invesco Nasdaq Biotechnology ETF
Anteil1.15%
ProShares Ultra Nasdaq Biotechnology
Anteil1.14%
National Security Emerging Markets Index ETF
Anteil0.92%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten